---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Guidelines questions"
description: "Guidelines questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What do NCCN guidelines recommend for Kisqali in metastatic breast cancer? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Guidelines questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications](https://www.evicenter.com/medical-information/kisqali).

## Guidelines

<a id="kisqali-nccn-guidelines"></a>

### What do NCCN guidelines recommend for Kisqali in metastatic breast cancer?

> “Preferred Regimens
> • Aromatase inhibitor + CDK4/6 inhibitor<sup>b</sup>
> – Aromatase inhibitor + ribociclib (category 1)<sup>c</sup>”

Source: [KISQALI: clinical flashcard, page 1, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=1)

> “If disease progression on adjuvant endocrine therapy or relapse  
> within 12 months of adjuvant endocrine therapy completion consider:
> • Fulvestrant<sup>d</sup> + CDK4/6 inhibitor<sup>b</sup>
> – Fulvestrant + ribociclib (category 1)<sup>e</sup>”

Source: [KISQALI: clinical flashcard, page 1, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=1)

> “In phase 3 randomized controlled trials, ribociclib + endocrine therapy have shown OS benefit in 
> the first-line setting.”

Source: [KISQALI: clinical flashcard, page 1, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=1)

> “Note: All recommendations are category 2A unless otherwise indicated.”

Source: [KISQALI: clinical flashcard, page 1, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=1)

> “Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Breast Cancer V.4.2025.”

Source: [KISQALI: clinical flashcard, page 4, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=4)

> “Accessed April 17, 2025.”

Source: [KISQALI: clinical flashcard, page 4, captured 2026-11-13](https://www.cdn.fuse.novartis.com/FA-11449454_Kisqali_PAN_Indication_Clinical_NCCN_Flashcard_Update_Digital_7.25/FA-11449454.PDF#page=4)

> “There is controversy on the choice of CDK4/6 inhibitor as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.<sup>1</sup>”

Source: [KISQALI: Expert Guidelines for KISQALI | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/expert-guidelines#:~:text=There%20is%20controversy%20on%20the,in%20the%20phase%20III%20randomized)

> “Category 1: Based upon high-level evidence (≥1 randomized phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.<sup>1</sup>”

Source: [KISQALI: Expert Guidelines for KISQALI | KISQALI® (ribociclib) | HCP, captured 2026-11-13](https://www.kisqali-hcp.com/expert-guidelines#:~:text=Category%201%3A%20Based%20upon%20high%2Dlevel,Panel%29%20that%20the%20intervention%20is)

Note: The first six passages are from the NCCN clinical flashcard (dated July 2025) that the expert guidelines page links, which reproduces NCCN Guidelines for Breast Cancer Version 4.2025 for ER- and/or PR-positive, HER2-negative recurrent unresectable or stage IV disease. The guideline lists other CDK4/6 inhibitor combinations in the same regimen lists. The last two passages are from the expert guidelines page, which cites Version 6.2026 (accessed July 30, 2026).

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
